Please assess the completion status of the following clinical trial:

Trial Title: This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to participate and to adhere to dose and visit schedules~* 18 to 65 years, either sex, any race~* 2-year history of SAR, being symptomatic during the last 2 ragweed seasons~* Skin test positive to short ragweed allergen at screening, or positive within 12 months~* Women must practice adequate contraception: Females of childbearing potential (including women who are less than 1 year postmenopausal and women who will be sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication. Women who are postmenopausal for \>1 year (ie, women who have experienced 12 consecutive months of amenorrhea) will be exempted from the use of contraception during the study.; Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with a spermicidal agent, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptives, and surgical sterilization (eg, hysterectomy or tubal ligation)~* Negative pregnancy tests during study~Exclusion Criteria:~* Compromised ability to provide informed consent~* Nasal abnormalities, including large nasal polyps, and marked septum deviation that interferes with nasal airflow at screening~* Recent (within the last 2 weeks) or unhealed nasal septum ulcers, nasal surgery, or nasal trauma~* Unstable asthma which cannot be controlled with inhaled short-acting beta-2 agonists~* Diagnosed with sinusitis within the previous 2 weeks~* Is initiating or is currently on advanced immunotherapy~* If on immunotherapy (desensitization therapy), the subject must be stable and should not receive an increase in dose during the study. Subjects may not receive desensitization treatment within 24 hours prior to a study visit~* Is currently on or has been on an antihistamine, decongestant (topical or systemic) or a nasal inhaled corticosteroid during the 14 days prior to the first priming visit~* Unable to refrain from regular use of nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids~* Failed the designated washout periods for any of the prohibited medications~* Upper or lower respiratory tract or sinus infection that required antibiotic therapy or a viral upper or lower respiratory infection within 14 days prior to screening~* Is allergic to or has sensitivity to the study drug or its excipients~* Used any investigational product within 30 days before enrollment or any antibodies for asthma or allergic rhinitis in the past 90 days~* Subject has Chronic obstructive pulmonary disease, Alcohol abuse, Rhinitis medicamentosa

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate Nasal Spray (MFNS) (Type: EXPERIMENTAL): MFNS 200 mcg total dose (2 sprays each nostril)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (2 sprays each nostril)

Based on this trial design, predict the completion outcome and termination type (if applicable).